Minxuan Xu

2.7k total citations · 2 hit papers
58 papers, 1.9k citations indexed

About

Minxuan Xu is a scholar working on Molecular Biology, Epidemiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Minxuan Xu has authored 58 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 20 papers in Epidemiology and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Minxuan Xu's work include Liver Disease Diagnosis and Treatment (18 papers), Diet, Metabolism, and Disease (10 papers) and Air Quality and Health Impacts (8 papers). Minxuan Xu is often cited by papers focused on Liver Disease Diagnosis and Treatment (18 papers), Diet, Metabolism, and Disease (10 papers) and Air Quality and Health Impacts (8 papers). Minxuan Xu collaborates with scholars based in China, United States and Hong Kong. Minxuan Xu's co-authors include Jun Tan, Chenxu Ge, Deshuai Lou, Linfeng Hu, Yuting Qin, Ling‐Dong Kong, Chenxu Ge, Jian‐Mei Li, Rong Yu and Qiang Li and has published in prestigious journals such as Nature Communications, Journal of the American Statistical Association and Hepatology.

In The Last Decade

Minxuan Xu

56 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies

2023 174 citations Deju Zhang, Xiao Liu et al. profile →
SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

2023 76 citations Yunfeng Shen, Minxuan Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minxuan Xu China	24	700	436	376	216	183	58	1.9k
Xiance Sun China	28	882 1.3×	346 0.8×	443 1.2×	88 0.4×	137 0.7×	66	2.0k
Tao Zeng China	28	783 1.1×	590 1.4×	188 0.5×	231 1.1×	134 0.7×	111	2.6k
Rong Li China	30	1.2k 1.8×	302 0.7×	182 0.5×	261 1.2×	253 1.4×	98	3.1k
Pabitra Bikash Pal India	15	844 1.2×	215 0.5×	149 0.4×	154 0.7×	191 1.0×	17	2.1k
Yun Luo China	35	1.5k 2.2×	435 1.0×	307 0.8×	115 0.5×	169 0.9×	101	3.2k
Qi Cao United States	24	450 0.6×	420 1.0×	253 0.7×	111 0.5×	164 0.9×	52	1.5k
Elisabetta Bigagli Italy	25	770 1.1×	155 0.4×	447 1.2×	180 0.8×	300 1.6×	69	2.3k
Wei Ding China	28	934 1.3×	270 0.6×	188 0.5×	172 0.8×	240 1.3×	88	2.2k
Dongmei Wu China	26	704 1.0×	207 0.5×	224 0.6×	129 0.6×	250 1.4×	44	2.0k
Sarita Gupta India	26	585 0.8×	183 0.4×	445 1.2×	424 2.0×	125 0.7×	72	2.1k

Countries citing papers authored by Minxuan Xu

Since Specialization

Citations

This map shows the geographic impact of Minxuan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minxuan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minxuan Xu more than expected).

Fields of papers citing papers by Minxuan Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minxuan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minxuan Xu. The network helps show where Minxuan Xu may publish in the future.

Co-authorship network of co-authors of Minxuan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Minxuan Xu. A scholar is included among the top collaborators of Minxuan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minxuan Xu. Minxuan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yi, Long, Minxuan Xu, Jitao Ling, et al.. (2025). Medicine‐Food Plant Polysaccharides Modulate Diabetes and Diabetic Complications Through Maintaining Gut Function: A Review. Food Frontiers. 6(6). 2720–2765. 1 indexed citations

Xu, Minxuan, Junjie Zhao, Liancai Zhu, et al.. (2024). Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression. Journal of Hepatology. 82(2). 277–300. 4 indexed citations

Li, Qiang, Yanbin Zheng, Jianyu Zhao, et al.. (2024). Radish red attenuates chronic kidney disease in obese mice through repressing oxidative stress and ferroptosis via Nrf2 signaling improvement. International Immunopharmacology. 143(Pt 3). 113385–113385. 7 indexed citations

Xu, Minxuan, et al.. (2024). Exploring shared molecular signatures and regulatory mechanisms in nonalcoholic steatohepatitis and inflammatory bowel disease using integrative bioinformatics analysis. Scientific Reports. 14(1). 12085–12085.

Xu, Minxuan, et al.. (2023). Arabinose confers protection against intestinal injury by improving integrity of intestinal mucosal barrier. International Immunopharmacology. 126. 111188–111188. 3 indexed citations

Luo, Wei, Jing Zhang, Zhangwang Li, et al.. (2023). Polysaccharides-based nanocarriers enhance the anti-inflammatory effect of curcumin. Carbohydrate Polymers. 311. 120718–120718. 48 indexed citations

He, Ruifeng, Minxuan Xu, Deju Zhang, et al.. (2023). Identification of necroptosis-related features in diabetic nephropathy and analysis of their immune microenvironent and inflammatory response. Frontiers in Cell and Developmental Biology. 11. 1271145–1271145. 2 indexed citations

Xu, Minxuan, Jun Tan, Liancai Zhu, et al.. (2023). Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S‐Palmitoylated IRHOM2. Advanced Science. 10(28). e2302130–e2302130. 13 indexed citations

Liu, Xingyu, WU Shu-qin, Deju Zhang, et al.. (2023). RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy. BioScience Trends. 17(1). 21–37. 5 indexed citations

10.

Zhang, Jing, Hongguang Sheng, Xiaoyi Tang, et al.. (2022). Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19. Frontiers in Cellular and Infection Microbiology. 12. 935280–935280. 2 indexed citations

11.

Luo, Jing, Jun Tan, Junjie Zhao, et al.. (2022). Cynapanoside A exerts protective effects against obesity-induced diabetic nephropathy through ameliorating TRIM31-mediated inflammation, lipid synthesis and fibrosis. International Immunopharmacology. 113(Pt B). 109395–109395. 4 indexed citations

12.

Ge, Chenxu, Jun Tan, Xianling Dai, et al.. (2022). Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK. Nature Communications. 13(1). 5945–5945. 41 indexed citations

13.

Li, Zhangwang, Minxuan Xu, Deju Zhang, et al.. (2022). O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease. Cells. 11(22). 3637–3637. 8 indexed citations

14.

Xu, Minxuan, et al.. (2022). Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma. Pathology & Oncology Research. 28. 1 indexed citations

15.

Li, Ling, Linfeng Hu, Qiang Li, et al.. (2021). Carminic acid mitigates fructose-triggered hepatic steatosis by inhibition of oxidative stress and inflammatory reaction. Biomedicine & Pharmacotherapy. 145. 112404–112404. 17 indexed citations

16.

Xu, Minxuan, Chenxu Ge, Yuting Qin, et al.. (2020). Functional loss of inactive rhomboid-like protein 2 mitigates obesity by suppressing pro-inflammatory macrophage activation-triggered adipose inflammation. Molecular Metabolism. 34. 112–123. 11 indexed citations

17.

Xu, Minxuan, Chenxu Ge, Qiang Li, et al.. (2019). Fisetin nanoparticles protect against PM2.5 exposure-induced neuroinflammation by down-regulation of astrocytes activation related NF-κB signaling pathway. Journal of Functional Foods. 65. 103716–103716. 14 indexed citations

18.

Xu, Minxuan, Rong Yu, Chenxu Ge, et al.. (2016). Up-regulated fractalkine (FKN) and its receptor CX3CR1 are involved in fructose-induced neuroinflammation: Suppression by curcumin. Brain Behavior and Immunity. 58. 69–81. 55 indexed citations

19.

Qi, Junjie, Huihui Zhang, Zhaoxia Ji, Minxuan Xu, & Yue Zhang. (2015). ZnO nano-array-based EGFET biosensor for glucose detection. Applied Physics A. 119(3). 807–811. 36 indexed citations

20.

Li, Jian‐Mei, Chenxu Ge, Minxuan Xu, et al.. (2014). Betaine recovers hypothalamic neural injury by inhibiting astrogliosis and inflammation in fructose‐fed rats. Molecular Nutrition & Food Research. 59(2). 189–202. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact